FDA approves ‘female Viagra,’ could tap potential $1 billion market

The U.S. drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals’ drug to restore sexual desire in premenopausal women, the la

‘Solve the problem at home’: U.S. plan to import cheaper drugs from Canada draws criticism
Britain proposes banning kids from liking social media posts
Trump says cryptocurrencies must face banking regulations, ‘not a fan’ of them

The U.S. drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals’ drug to restore sexual desire in premenopausal women, the latest attempt to come up with a therapy that some have dubbed as “female Viagra.”READ MORE: Why some people have sex even when they aren’t in the moodThe therapy, Vyleesi, will compete in a market which has seen previous attempts fail. Analysts have said that a drug that safely and effectively treats loss of sexual desire in women could eventually reach annual sales of about $1 billion.Palatin’s shares jumped 44 per cent to $1.93, while Amag shares rose 11.5 per cent after market.Vyleesi, chemically known as bremelanotide, activates pathways in the brain involved in sexual desire, helping premenopausal women with hypoactive sexual desire disorder (HSDD).WATCH: 20 years since the little blue pill got the green light

COMMENTS

WORDPRESS: 0
DISQUS: 0